These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 8087240)

  • 1. Assessment of blood substitutes: II. In-vitro complement activation of human plasma and blood for safety studies in research, development, industrial production and preclinical analysis.
    Chang TM; Lister CW
    Artif Cells Blood Substit Immobil Biotechnol; 1994; 22(2):171-80. PubMed ID: 8087240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A screening test for modified hemoglobin blood substitutes before clinical use: based on C3a complement activation in human plasma.
    Chang TM; Lister C
    Biomater Artif Cells Artif Organs; 1990; 18(5):693-701. PubMed ID: 2099226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of finger-prick human blood samples as a more convenient way for in-vitro screening of modified hemoglobin blood substitutes for complement activation: a preliminary report.
    Chang TM; Lister CW
    Biomater Artif Cells Immobilization Biotechnol; 1993; 21(5):685-90. PubMed ID: 8117858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A preclinical screening test for modified hemoglobin to bridge the gap between animal safety studies and use in human.
    Chang TM; Lister C
    Biomater Artif Cells Immobilization Biotechnol; 1992; 20(2-4):565-73. PubMed ID: 1391479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood substitutes based on modified hemoglobin prepared by encapsulation or crosslinking: an overview.
    Chang TM
    Biomater Artif Cells Immobilization Biotechnol; 1992; 20(2-4):159-79. PubMed ID: 1391433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The action of karbogal on the complement system under model conditions and in an animal experiment].
    Bel'tiukov PP; Boromaz TA; Galebskaia LV; Riumina EV; Sachkov AV; Shcherbak IG
    Gematol Transfuziol; 1992; 37(7-8):27-8. PubMed ID: 1342982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Haemoglobin-based red cell substitutes: current status.
    Ogden JE; Mac Donald SL
    Vox Sang; 1995; 69(4):302-8. PubMed ID: 8751299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of homologous and heterologous stroma-free hemoglobin and polyhemoglobin on complement activation, leucocytes and platelets.
    Ning J; Chang TM
    Biomater Artif Cells Artif Organs; 1990; 18(2):219-32. PubMed ID: 2369648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Blood substitutes: state of the art and technical setbacks and why we are still disappointed].
    Vigneron C; Smani Y; Faivre B
    Bull Acad Natl Med; 2007; 191(4-5):837-47; discussion 847. PubMed ID: 18225438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety studies of modified hemoglobin as an oxygen-carrying blood substitute.
    Chang TM
    Hematol Pathol; 1993; 7(1):49-55. PubMed ID: 8468266
    [No Abstract]   [Full Text] [Related]  

  • 11. Denatured hemoglobin increases human blood mononuclear cell procoagulant effect.
    Kim SA; Villa VO; Hess JR
    Artif Cells Blood Substit Immobil Biotechnol; 1994; 22(3):625-31. PubMed ID: 7994383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alternative strategies in drug development: clinical pharmacological aspects.
    Kuhlmann J
    Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long term safety and immunological effects of a nanobiotherapeutic, bovine poly-[hemoglobin-catalase-superoxide dismutase-carbonic anhydrase], after four weekly 5% blood volume top-loading followed by a challenge of 30% exchange transfusion.
    Guo C; Chang TMS
    Artif Cells Nanomed Biotechnol; 2018 Nov; 46(7):1349-1363. PubMed ID: 29873524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Red cell substitutes.
    Winslow RM
    Semin Hematol; 2007 Jan; 44(1):51-9. PubMed ID: 17198847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunological biocompatibility in blood substitutes.
    Vercellotti GM; Hammerschmidt DE
    Int Anesthesiol Clin; 1985; 23(1):47-62. PubMed ID: 3980107
    [No Abstract]   [Full Text] [Related]  

  • 16. Measurement of interleukin-6 production by monocytes for in vitro safety testing of hemoglobin solutions.
    Bleeker WK; de Groot EM; den Boer PJ; Biessels PT; Aarden LA; Bakker JC
    Artif Cells Blood Substit Immobil Biotechnol; 1994; 22(3):835-40. PubMed ID: 7994407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Co-oximetry interference by hemoglobin-based blood substitutes.
    Ali AA; Ali GS; Steinke JM; Shepherd AP
    Anesth Analg; 2001 Apr; 92(4):863-9. PubMed ID: 11273915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blood substitutes. What they are and how they might be used.
    Dong Q; Stowell CP
    Am J Clin Pathol; 2002 Dec; 118 Suppl():S71-80. PubMed ID: 14569814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blood substitutes: evolution and future applications.
    Scott MG; Kucik DF; Goodnough LT; Monk TG
    Clin Chem; 1997 Sep; 43(9):1724-31. PubMed ID: 9299967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Artificial inhibition of the complement system].
    Kozlov LV; Burdelev OO; Bureeva SV; Kaplun AP
    Bioorg Khim; 2007; 33(5):485-510. PubMed ID: 18050655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.